¾Ï ½ÃÀåÁ¶»çº¸°í¼­

¾ÏÄ¡·á °ü·Ã Á¶»çº¸°í¼­¿¡¼­´Â ±âÁ¸ ¶Ç´Â ½Å±Ô ¾ÏÁø´Ü ¹× Ä¡·á ¹æ¹ý¿¡ °üÇÑ »ó¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶Ç ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ¹× ƯÇã ½ÇÈ¿, »ç¾÷ Á¦ÈÞ, »õ·Î¿î Ä¡·á ¹æ½Ä, Ä¡·á Åø µîÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ·Â¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, 500°Ç ÀÌ»óÀÇ º¸°í¼­¸¦ ±¸ºñÇϰí ÀÖ½À´Ï´Ù.

1 - 25 (Àüü: 1,660°Ç)
¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º °ñ¼ö ¾ïÁ¦ Ä¡·á ½ÃÀå
Chemotherapy Induced Myelosuppression Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ À°Á¾ Ä¡·á ½ÃÀå
Sarcoma Therapeutics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±¸°­¾Ï Ä¡·áÁ¦ ½ÃÀå
Oral Cancer Therapeutics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸®°¡¾ÆÁ¦ È¿¼Ò ½ÃÀå
Ligases Enzyme
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Á¾¾ç À¯¹ß¼º °ñ¿¬È­Áõ ½ÃÀå
Tumor-Induced Osteomalacia
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ »ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ½ÃÀå
Triple Negative Breast Cancer Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀÎÈÄ¾Ï Ä¡·áÁ¦ ½ÃÀå
Throat Cancer Therapeutics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Àü¸³¼±¾Ï Ä¡·á ½ÃÀå
Prostate Cancer Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀå
Poly ADP-Ribose Polymerase (PARP) Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æ÷½ºÆ÷µð¿¡½ºÅ×¶óÁ¦(PDE) ¾ïÁ¦Á¦ ½ÃÀå
Phosphodiesterase (PDE) Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ PD-1 ÀúÇ×¼º µÎ°æºÎ¾Ï ½ÃÀå
PD-1 Resistant Head and Neck Cancer
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±¸°­¾Ï ½Å¼Ó °Ë»ç ŰƮ ½ÃÀå
Oral Cancer Rapid Test Kits
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ºñÀÎµÎ¾Ï ½ÃÀå
Nasopharynx Cancer
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ´Ù¹ß¼º°ñ¼öÁ¾ Ä¡·áÁ¦ ½ÃÀå
Multiple Myeloma Drugs
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¹ÌÅäź ½ÃÀå
Mitotane
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ °©»ó¼± ¼öÁú¾Ï ½ÃÀå
Medullary Thyroid Cancer
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÈÄµÎ¾Ï Ä¡·áÁ¦ ½ÃÀå
Laryngeal Cancer Therapeutics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¿ä·Î»óÇÇ¾Ï Áø´Ü ½ÃÀå
Urothelial Carcinoma Diagnostics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¿¬ºÎ À°Á¾ ½ÃÀå
Soft Tissue Sarcoma
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ·Î»çÀ̵¹ÇÁ¸¸º´ ½ÃÀå
Rosai-Dorfman Disease
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ³­Ä¡¼º ¿©Æ÷¼º ¸²ÇÁÁ¾ Áø´Ü ½ÃÀå
Refractory Follicular Lymphoma Diagnostics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¹Ý·Áµ¿¹°¿ë ¾Ï Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Pet Cancer Therapeutics Global Market Report 2025
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 4,490 £Ü 6,308,000 (ºÎ°¡¼¼ º°µµ)
³­¼Ò¾Ï ½ÃÀå : KOL ÀλçÀÌÆ®
KOL Insight - Ovarian Cancer
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 39,950 £Ü 56,125,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀüÀ̼º ´ëÀå¾Ï Ä¡·áÁ¦ ½ÃÀå
Metastatic Colorectal Cancer Drugs
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸ÇƲ¼¼Æ÷ ¸²ÇÁÁ¾ ½ÃÀå
Mantle Cell Lymphoma
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.